Merck Manual

Please confirm that you are a health care professional

honeypot link



James L. Lewis III

, MD, Brookwood Baptist Health and Saint Vincent’s Ascension Health, Birmingham

Reviewed/Revised Sep 2021 | Modified Sep 2022
View Patient Education
Topic Resources

Hypercalcemia is a total serum calcium concentration > 10.4 mg/dL (> 2.60 mmol/L) or ionized serum calcium > 5.2 mg/dL (> 1.30 mmol/L). Principal causes include hyperparathyroidism, vitamin D toxicity, and cancer. Clinical features include polyuria, constipation, muscle weakness, confusion, and coma. Diagnosis is by measuring serum ionized calcium and parathyroid hormone concentrations. Treatment to increase calcium excretion and reduce bone resorption of calcium involves saline, sodium diuresis, and drugs such as zoledronate.

Etiology of Hypercalcemia

Hypercalcemia usually results from excessive bone resorption. There are many causes of hypercalcemia (see table Principal Causes of Hypercalcemia Principal Causes of Hypercalcemia Principal Causes of Hypercalcemia ), but the most common are

  • Hyperparathyroidism

  • Cancer


Pathophysiology of Hypercalcemia

Primary hyperparathyroidism

Primary hyperparathyroidism is a generalized disorder resulting from excessive secretion of parathyroid hormone (PTH) by one or more parathyroid glands. It probably is the most common cause of hypercalcemia, particularly among patients who are not hospitalized. Incidence increases with age and is higher in postmenopausal women. It also occurs in high frequency 3 decades after neck irradiation. Familial and sporadic forms exist.

PTH increases serum calcium by increasing intestinal absorption of calcium; rapidly mobilizing calcium and phosphate from bone (bone resorption); enhancing renal distal nephron calcium reabsorption; and stimulating conversion of vitamin D Vitamin D Deficiency and Dependency Inadequate exposure to sunlight predisposes to vitamin D deficiency. Deficiency impairs bone mineralization, causing rickets in children and osteomalacia in adults and possibly contributing... read more to its most active form, calcitriol (which increases the percentage of dietary calcium absorbed by the intestine).

Familial forms due to parathyroid adenoma Mitral Stenosis Mitral stenosis is narrowing of the mitral orifice that impedes blood flow from the left atrium to the left ventricle. The usual cause is rheumatic fever. Common complications are pulmonary... read more occur in patients with other endocrine tumors (see also Overview of Multiple Endocrine Neoplasia Overview of Multiple Endocrine Neoplasias (MEN) The multiple endocrine neoplasia (MEN) syndromes comprise 3 genetically distinct familial diseases involving adenomatous hyperplasia and malignant tumors in several endocrine glands. MEN 1 involves... read more ). Primary hyperparathyroidism causes hypophosphatemia Hypophosphatemia Hypophosphatemia is a serum phosphate concentration < 2.5 mg/dL (0.81 mmol/L). Causes include alcohol use disorder, burns, starvation, and diuretic use. Clinical features include muscle weakness... read more and excessive bone resorption. Although asymptomatic hypercalcemia is the most frequent presentation, nephrolithiasis Urinary Calculi Urinary calculi are solid particles in the urinary system. They may cause pain, nausea, vomiting, hematuria, and, possibly, chills and fever due to secondary infection. Diagnosis is based on... read more is also common, particularly when hypercalciuria occurs due to long-standing hypercalcemia. Histologic examination shows a parathyroid adenoma in about 85% of patients with primary hyperparathyroidism, although it is sometimes difficult to distinguish an adenoma from a normal gland. About 15% of cases are due to hyperplasia of 2 glands. Parathyroid cancer occurs in < 1% of cases.

Familial hypocalciuric hypercalcemia

The syndrome of familial hypocalciuric hypercalcemia (FHH) is transmitted as an autosomal dominant trait. FHH involves an inactivating mutation of the calcium-sensing receptor gene CASR (most commonly), GNA11, or AP2S1 (peptides related to control or expression of CASR), resulting in higher concentrations of serum calcium being needed to inhibit PTH secretion. Subsequent PTH secretion induces renal phosphate excretion. Persistent hypercalcemia (usually asymptomatic) and often from an early age, normal to slightly elevated concentrations of PTH, hypocalciuria, and hypermagnesemia Hypermagnesemia Hypermagnesemia is a serum magnesium concentration > 2.6 mg/dL (> 1.05 mmol/L). The major cause is renal failure. Symptoms include hypotension, respiratory depression, and cardiac arrest... read more occur. Renal function is normal, and nephrolithiasis is unusual. However, severe pancreatitis Overview of Pancreatitis Pancreatitis is classified as either acute or chronic. Acute pancreatitis is inflammation that resolves both clinically and histologically. Chronic pancreatitis is characterized by histologic... read more occasionally occurs. This syndrome, which is associated with parathyroid hyperplasia, is not relieved by subtotal parathyroidectomy.

Secondary hyperparathyroidism

Secondary hyperparathyroidism occurs most commonly in advanced chronic kidney disease Chronic Kidney Disease Chronic kidney disease (CKD) is long-standing, progressive deterioration of renal function. Symptoms develop slowly and in advanced stages include anorexia, nausea, vomiting, stomatitis, dysgeusia... read more Chronic Kidney Disease when decreased formation of active vitamin D in the kidneys and other factors lead to hypocalcemia and chronic stimulation of PTH secretion. Hyperphosphatemia Hyperphosphatemia Hyperphosphatemia is a serum phosphate concentration > 4.5 mg/dL (> 1.46 mmol/L). Causes include chronic kidney disease, hypoparathyroidism, and metabolic or respiratory acidosis. Clinical... read more that develops in response to chronic kidney disease also contributes. Once the hyperparathyroidism is established, hypercalcemia or normocalcemia may occur. The sensitivity of the parathyroid to calcium may be diminished because of pronounced glandular hyperplasia and elevation of the calcium set point (ie, the amount of calcium necessary to reduce secretion of PTH).

Tertiary hyperparathyroidism

Tertiary hyperparathyroidism results in autonomous hypersecretion of PTH regardless of serum calcium concentration. Tertiary hyperparathyroidism generally occurs in patients with long-standing secondary hyperparathyroidism, as in patients with end-stage renal disease of several years’ duration.


Cancer is a common cause of hypercalcemia, usually in hospitalized patients. Although there are several mechanisms, elevated serum calcium ultimately occurs as a result of bone resorption.

Osteolytic hypercalcemia can be caused by metastatic solid tumors (eg, breast, prostate, non-small cell lung cancers) or hematologic cancers, most often multiple myeloma Multiple Myeloma Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. Common manifestations include lytic lesions in bones causing... read more Multiple Myeloma , but also certain lymphomas Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. The major types are Hodgkin lymphoma Non-Hodgkin lymphoma See table Comparison of Hodgkin... read more and lymphosarcomas. Hypercalcemia may result from local elaboration of osteoclast-activating cytokines or prostaglandins that stimulate osteoclasts to resorb bone, direct bone resorption by the tumor cells, or both. Diffuse osteopenia may also occur.

Vitamin D toxicity

Vitamin D toxicity Vitamin D Toxicity Usually, vitamin D toxicity results from taking excessive amounts. In vitamin D toxicity, resorption of bone and intestinal absorption of calcium is increased, resulting in hypercalcemia. Marked... read more can be caused by high concentrations of endogenous 1,25(OH)2D. Although serum concentrations are low in most patients with solid tumors, patients with lymphomas Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. The major types are Hodgkin lymphoma Non-Hodgkin lymphoma See table Comparison of Hodgkin... read more or T-cell leukemia sometimes have elevated concentrations due to dysregulation of the 1-alpha-hydroxylase enzyme present in tumor cells. Exogenous vitamin D in pharmacologic doses causes excessive bone resorption as well as increased intestinal calcium absorption, resulting in hypercalcemia and hypercalciuria.

Granulomatous disorders

Granulomatous disorders, such as sarcoidosis Sarcoidosis Sarcoidosis is an inflammatory disorder resulting in noncaseating granulomas in one or more organs and tissues; etiology is unknown. The lungs and lymphatic system are most often affected, but... read more Sarcoidosis , tuberculosis Tuberculosis (TB) Tuberculosis is a chronic, progressive mycobacterial infection, often with an asymptomatic latent period following initial infection. Tuberculosis most commonly affects the lungs. Symptoms include... read more Tuberculosis (TB) , leprosy Leprosy Leprosy is a chronic infection usually caused by the acid-fast bacilli Mycobacterium leprae or the closely related organism M. lepromatosis. These organisms have a unique tropism... read more Leprosy , berylliosis Beryllium Disease Acute and chronic beryllium disease are caused by inhalation of dust or fumes from beryllium compounds and products. Acute beryllium disease is now rare; chronic beryllium disease is characterized... read more , histoplasmosis Histoplasmosis Histoplasmosis is a pulmonary and hematogenous disease caused by Histoplasma capsulatum; it is often chronic and usually follows an asymptomatic primary infection. Symptoms are those... read more Histoplasmosis , and coccidioidomycosis Coccidioidomycosis Coccidioidomycosis is a pulmonary or hematogenously spread disseminated disease caused by the fungi Coccidioides immitis and C. posadasii; it usually occurs as an acute benign... read more Coccidioidomycosis , lead to hypercalcemia and hypercalciuria. In sarcoidosis, hypercalcemia and hypercalciuria appear to be due to unregulated conversion of 25(OH)D to 1,25(OH)2D, presumably due to expression of the 1-alpha-hydroxylase enzyme in mononuclear cells within sarcoid granulomas. Similarly, elevated serum concentrations of 1,25(OH)2D have been reported in patients with hypercalcemia and tuberculosis or silicosis Silicosis Silicosis is caused by inhalation of unbound (free) crystalline silica dust and is characterized by nodular pulmonary fibrosis. Chronic silicosis initially causes no symptoms or only mild dyspnea... read more Silicosis . Other mechanisms must account for hypercalcemia in some instances, because depressed 1,25(OH)2D concentrations occur in some patients with hypercalcemia and leprosy.


Immobilization, particularly complete prolonged bed rest in patients at risk (see table Principal Causes of Hypercalcemia Principal Causes of Hypercalcemia Principal Causes of Hypercalcemia ), can result in hypercalcemia due to accelerated bone resorption. Hypercalcemia develops within days to weeks of onset of bed rest. Reversal of hypercalcemia occurs promptly on resumption of weight bearing. Young adults with several bone fractures and people with Paget disease of bone Paget Disease of Bone Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more Paget Disease of Bone are particularly prone to hypercalcemia when at bed rest.

Idiopathic infantile hypercalcemia

Idiopathic infantile hypercalcemia (Williams syndrome—see table Microdeletion Syndromes ) is an extremely rare sporadic disorder with dysmorphic facial features, cardiovascular abnormalities, renovascular hypertension, and hypercalcemia. It leads to nephrocalcinosis in some patients. The cause of hypercalcemia is unknown.

Milk-alkali syndrome

In milk-alkali syndrome, excessive amounts of calcium and absorbable alkali are ingested, usually during self-treatment with calcium carbonate antacids for dyspepsia or to prevent osteoporosis Osteoporosis Osteoporosis is a progressive metabolic bone disease that decreases bone mineral density (bone mass per unit volume), with deterioration of bone structure. Skeletal weakness leads to fractures... read more Osteoporosis , resulting in hypercalcemia, metabolic alkalosis Metabolic Alkalosis Metabolic alkalosis is primary increase in bicarbonate (HCO3) with or without compensatory increase in carbon dioxide partial pressure (Pco2); pH may be high or nearly normal. Common... read more , and renal insufficiency. The availability of effective drugs for peptic ulcer disease and osteoporosis has greatly reduced the incidence of this syndrome.

Symptoms and Signs of Hypercalcemia

In mild hypercalcemia, many patients are asymptomatic. Clinical manifestations of hypercalcemia include constipation, anorexia, nausea and vomiting, abdominal pain, and ileus. Impairment of the renal concentrating mechanism leads to polyuria, nocturia, and polydipsia. Elevation of serum calcium > 12 mg/dL (> 3.00 mmol/L) can cause emotional lability, confusion, delirium, psychosis, stupor, and coma. Hypercalcemia may cause neuromuscular symptoms, including skeletal muscle weakness. Hypercalciuria with nephrolithiasis is common.

Less often, prolonged or severe hypercalcemia causes reversible acute kidney injury or irreversible kidney damage due to nephrocalcinosis (precipitation of calcium salts within the kidney parenchyma).

In severe hypercalcemia a shortened QTc interval is shown on ECG, and arrhythmias may occur, particularly in patients taking digoxin. Hypercalcemia > 18 mg/dL (> 4.50 mmol/L) may cause shock, renal failure, and death.

Diagnosis of Hypercalcemia

  • Total serum (and sometimes ionized) calcium concentration

  • Chest x-ray; measurement of electrolytes, blood urea nitrogen (BUN), creatinine, phosphate, PTH, alkaline phosphatase, and serum protein immunoelectrophoresis to determine the cause

  • Sometimes urinary excretion of calcium with or without phosphate

Hypercalcemia is diagnosed by a serum calcium concentration > 10.4 mg/dL (> 2.60 mmol/L) or ionized serum calcium > 5.2 mg/dL (> 1.30 mmol/L). The condition is frequently discovered during routine laboratory screening.

Serum calcium can be artifactually elevated by high serum protein levels (see table Laboratory and Clinical Findings in Some Disorders Causing Hypercalcemia Laboratory and Clinical Findings in Some Disorders Causing Hypercalcemia Laboratory and Clinical Findings in Some Disorders Causing Hypercalcemia ). True ionized hypercalcemia can also be masked by low serum protein. When protein and albumin are abnormal and when ionized hypercalcemia is suspected because of clinical findings (eg, because of symptoms of hypercalcemia), ionized serum calcium should be measured.

Initial evaluation

Initial evaluation should include

  • Review of the history, particularly of past serum calcium concentrations

  • Physical examination

  • Chest x-ray

  • Laboratory studies, including electrolytes, BUN, creatinine, ionized calcium, phosphate, PTH, alkaline phosphatase, and serum protein immunoelectrophoresis

The cause is apparent from clinical data and results of these tests in ≥ 95% of patients. Patients without an obvious cause of hypercalcemia after this evaluation should undergo measurement of intact parathyroid hormone and 24-hour urinary calcium. When no cause is obvious, serum calcium < 11 mg/dL (< 2.75 mmol/L) suggests hyperparathyroidism or other nonmalignant causes, whereas serum calcium > 13 mg/dL (> 3.25 mmol/L) suggests cancer.

Asymptomatic hypercalcemia that has been present for years or is present in several family members raises the possibility of familial hypocalciuric hypercalcemia. Primary hyperparathyroidism generally manifests late in life but can be present for several years before symptoms occur.

Measurement of intact PTH levels help differentiate PTH-mediated hypercalcemia (eg, caused by hyperparathyroidism or familial hypocalciuric hypercalcemia), in which PTH levels are high or high-normal, from most other (PTH-independent) causes. In PTH-independent causes, levels are usually < 20 pg/mL.(< 2.1 pmol/L)

Chest and bone (eg, skull, extremity) x-rays can also show the effects on bone of secondary hyperparathyroidism, most commonly in patients receiving long-term dialysis. In osteitis fibrosa cystica (often due to primary hyperparathyroidism), increased osteoclastic activity from overstimulation by PTH causes rarefaction of bone with fibrous degeneration and cyst and fibrous nodule formation. Because characteristic bone lesions occur only with relatively advanced disease, bone x-rays are recommended only for symptomatic patients. X-rays typically show bone cysts, a heterogeneous appearance of the skull, and subperiosteal resorption of bone in the phalanges and distal clavicles.


In hyperparathyroidism, the serum calcium is rarely > 12 mg/dL (> 3 mmol/L), but the ionized serum calcium is almost always elevated. Low serum phosphate concentration suggests hyperparathyroidism, especially when coupled with elevated renal excretion of phosphate. When hyperparathyroidism results in increased bone turnover, serum alkaline phosphatase is frequently increased. Increased intact PTH, particularly inappropriate elevation (ie, a high concentration in the absence of hypocalcemia) or an inappropriate high-normal concentration (ie, despite hypercalcemia), is diagnostic.

Urinary calcium excretion is usually normal or high in hyperparathyroidism. Chronic kidney disease Chronic Kidney Disease Chronic kidney disease (CKD) is long-standing, progressive deterioration of renal function. Symptoms develop slowly and in advanced stages include anorexia, nausea, vomiting, stomatitis, dysgeusia... read more Chronic Kidney Disease suggests the presence of secondary hyperparathyroidism, but primary hyperparathyroidism can also be present. In patients with chronic kidney disease, high serum calcium and normal serum phosphate suggest primary hyperparathyroidism, whereas elevated phosphate suggests secondary hyperparathyroidism.

Multiple endocrine neoplasia Overview of Multiple Endocrine Neoplasias (MEN) The multiple endocrine neoplasia (MEN) syndromes comprise 3 genetically distinct familial diseases involving adenomatous hyperplasia and malignant tumors in several endocrine glands. MEN 1 involves... read more (MEN) should be considered in patients with primary hyperparathyroidism. Primary hyperparathyroidism is more common in women, occurs most commonly in people ages 30 to 50 years and typically presents with a single abnormal gland while MEN occurs equally in both sexes, typically occurs in younger adults and frequently manifests with multiple abnormal glands as well as recurrent parathyroid adenomas.

The need for localization of parathyroid tissue before surgery on the parathyroid(s) is controversial. High-resolution CT with or without CT-guided biopsy and immunoassay of thyroid venous drainage, MRI, high-resolution ultrasonography, digital subtraction angiography, and thallium-201–technetium-99 scanning all have been used and are highly accurate, but they have not improved the usually high cure rate of parathyroidectomy done by experienced surgeons. Technetium-99 sestamibi, a radionuclide agent for parathyroid imaging, is more sensitive and specific than older agents and may be useful for identifying solitary adenomas.

For residual or recurrent hyperparathyroidism after initial parathyroid surgery, imaging is necessary and may reveal abnormally functioning parathyroid glands in unusual locations throughout the neck and mediastinum. Technetium-99 sestamibi is probably the most sensitive imaging test. Use of several imaging studies (MRI, CT, or high-resolution ultrasonography in addition to technetium-99 sestamibi) before repeat parathyroidectomy is sometimes necessary.


A serum calcium measurement > 13 mg/dL (> 3 mmol/L) suggests some cause of hypercalcemia other than hyperparathyroidism. Urinary calcium excretion is usually normal or high in cancer. In humoral hypercalcemia of cancer, PTH is often decreased or undetectable; phosphate is often decreased; and metabolic alkalosis, hypochloremia, and hypoalbuminemia are often present. Suppressed PTH differentiates humoral hypercalcemia of cancer from primary hyperparathyroidism. Humoral hypercalcemia of cancer can also be diagnosed by detection of PTH-related peptide in serum.

Multiple myeloma Multiple Myeloma Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. Common manifestations include lytic lesions in bones causing... read more Multiple Myeloma is suggested by simultaneous anemia, azotemia, and hypercalcemia or by the presence of a monoclonal gammopathy. Myeloma is confirmed by bone marrow examination.

Familial hypocalciuric hypercalcemia (FHH)

FHH is very rare but should be considered in patients with hypercalcemia and elevated or high-normal intact PTH levels. FHH is distinguished from primary hyperparathyroidism by the

  • Early age of onset

  • Absence of symptoms

  • Frequent occurrence of hypermagnesemia

  • Presence of hypercalcemia without hypercalciuria in other family members

  • Low fractional excretion of calcium, which is the ratio of calcium clearance to creatinine clearance (< 1% in FHH; 1 to 4% in primary hyperparathyroidism)

  • Elevated or normal intact PTH

Altered feedback regulation of the parathyroid glands may be responsible for the elevated or normal intact PTH level.

Testing for mutations of the CASR, GNA11, or AP2S1 genes may identify the genetic cause of the autosomal dominant forms of the disease that affect a specific family.

Milk-alkali syndrome

In addition to a history of increased intake of calcium antacids, milk-alkali syndrome is recognized by the combination of hypercalcemia, metabolic alkalosis, and, occasionally, azotemia with hypocalciuria. The diagnosis can be confirmed when the serum calcium concentration rapidly returns to normal when calcium and alkali ingestion stops, although renal insufficiency can persist when nephrocalcinosis is present. Circulating PTH usually is suppressed.

Other causes

Vitamin D toxicity is characterized by elevated 25(OH)D concentration. In hypercalcemia due to sarcoidosis, other granulomatous disorders, and some lymphomas, serum concentration of 1,25(OH)2D may be elevated.


Treatment of Hypercalcemia

  • Oral phosphate for serum calcium < 11.5 mg/dL (< 2.9 mmol/L) with mild symptoms and no kidney disease

  • IV saline and furosemide for more rapid correction of elevated serum calcium < 18 mg/dL (< 4.5 mmol/L)

  • Bisphosphonates or other calcium-lowering drugs for serum calcium 11.5 to 18 mg/dL (3.7 to 5.8 mmol/L) and/or moderate symptoms

  • Hemodialysis for serum calcium >18 mg/dL (> 5.8 mmol/L)

  • Surgical removal of parathyroid glands for moderate, progressive primary hyperparathyroidism and sometimes for mild hyperparathyroid disease

  • Phosphate restriction and binders and sometimes calcitriol for secondary hyperparathyroidism

There are 4 main strategies for lowering serum calcium:

  • Decrease intestinal calcium absorption

  • Increase urinary calcium excretion

  • Decrease bone resorption

  • Remove excess calcium through dialysis

The treatment used depends on both the degree and the cause of hypercalcemia. Volume repletion with saline is an essential element of care.

Mild hypercalcemia

In mild hypercalcemia (serum calcium < 11.5 mg/dL [< 2.9 mmol/L]), in which symptoms are mild or absent, treatment is deferred pending definitive diagnosis. After diagnosis, the underlying disorder is treated.

When symptoms are significant, treatment aimed at lowering serum calcium is necessary. Oral phosphate can be used. When taken with meals, phosphate binds some calcium, preventing its absorption. A starting dose is 250 mg of elemental phosphate (as sodium or potassium salt) 4 times a day. The dose can be increased to 500 mg 4 times a day as needed unless diarrhea develops.

Another treatment is increasing urinary calcium excretion by giving isotonic saline plus a loop diuretic. Initially, 1 to 2 L of saline is given over 2 to 4 hours unless significant heart failure is present because nearly all patients with significant hypercalcemia are hypovolemic. Furosemide 20 to 40 mg IV every 2 to 4 hours is given as needed to maintain a urine output of roughly 250 mL/hour (monitored hourly). Care must be taken to avoid volume depletion. Potassium and magnesium are monitored as often as every 4 hours during treatment and replaced IV as needed to avoid hypokalemia Hypokalemia Hypokalemia is serum potassium concentration < 3.5 mEq/L (< 3.5 mmol/L) caused by a deficit in total body potassium stores or abnormal movement of potassium into cells. The most common... read more and hypomagnesemia Hypomagnesemia Hypomagnesemia is serum magnesium concentration < 1.8 mg/dL (< 0.70 mmol/L). Causes include inadequate magnesium intake and absorption or increased excretion due to hypercalcemia or drugs... read more . Serum calcium begins to decrease in 2 to 4 hours and falls to near-normal within 24 hours.

Moderate hypercalcemia

Moderate hypercalcemia (serum calcium > 11.5 mg/dL [> 2.88 mmol/L] and < 18 mg/dL [< 4.51 mmol/L]) can be treated with isotonic saline and a loop diuretic as is done for mild hypercalcemia or, depending on its cause, with drugs that decrease bone resorption (usually bisphosphonates, calcitonin, or infrequently plicamycin or gallium nitrate), corticosteroids, or chloroquine.

Bisphosphonates inhibit osteoclasts. They are usually the drugs of choice for cancer-associated hypercalcemia. Zoledronate can be given as a one-time dose of 4 to 8 mg IV and lowers serum calcium very effectively for an average of > 40 days.

Pamidronate can be given for cancer-associated hypercalcemia as a one-time dose of 30 to 90 mg IV, repeated only after 7 days. It lowers serum calcium for 2 weeks.

Ibandronate as a one-time dose of 4 to 6 mg IV can be given for cancer-associated hypercalcemia; it is effective for about 14 days.

Etidronate 7.5 mg/kg IV once a day for 3 to 5 days is used to treat Paget disease and cancer-associated hypercalcemia. Maintenance dosage is 20 mg/kg orally once a day, but the dose must be reduced when glomerular filtration rate is low.

Repetitive use of IV bisphosphonates to treat hypercalcemia associated with metastatic bone disease or myeloma has been associated with osteonecrosis of the jaw Medication-Related Osteonecrosis of the Jaw (MRONJ) Medication-related osteonecrosis of the jaw has no unanimously accepted definition or etiology but is generally held to be an oral lesion involving bare mandibular or maxillary bone present... read more . Some reports suggest this finding may be more common with zoledronate. Renal toxicity has been reported in patients receiving zoledronate. Oral bisphosphonates (eg, alendronate or risedronate) can be given to maintain calcium in the normal range but are not generally used for treating hypercalcemia acutely.

Denosumab, 120 mg subcutaneously every 4 weeks with additional doses on days 8 and 15 of the first month of treatment, is a monoclonal antibody inhibitor of osteoclastic activity that can be used for cancer-associated hypercalcemia that does not respond to bisphosphonates. Calcium and vitamin D are given as needed to avert hypocalcemia.

Calcitonin (thyrocalcitonin) is a rapidly acting peptide hormone normally secreted in response to hypercalcemia by the C cells of the thyroid. Calcitonin appears to lower serum calcium by inhibiting osteoclastic activity. A dosage of 4 to 8 IU/kg subcutaneously every 12 hours of salmon calcitonin is safe. Calcitonin can lower serum calcium levels by 1 to 2 mg/dL within a few hours. Its usefulness in the treatment of cancer-associated hypercalcemia is limited by its short duration of action with the development of tachyphylaxis (often after about 48 hours) and by the lack of response in 40% of patients. However, the combination of salmon calcitonin and prednisone may control serum calcium for several months in some patients with cancer. If calcitonin stops working, it can be stopped for 2 days (while prednisone is continued) and then resumed.

Corticosteroids (eg, prednisone 20 to 40 mg orally once a day) can help control hypercalcemia as adjunctive therapy by decreasing calcitriol production and thus intestinal calcium absorption in most patients with vitamin D toxicity, idiopathic hypercalcemia of infancy, and sarcoidosis. Some patients with myeloma, lymphoma, leukemia, or metastatic cancer require 40 to 60 mg of prednisone once a day. However, > 50% of such patients fail to respond to corticosteroids, and response, when it occurs, takes several days; thus, other treatment usually is necessary.

Chloroquine phosphate 500 mg orally once a day inhibits 1,25(OH)2D synthesis and reduces serum calcium concentration in patients with sarcoidosis. Routine ophthalmologic surveillance (eg, retinal examinations every 6 to 12 months) is mandatory to detect dose-related retinal damage.

Plicamycin 25 mcg/kg IV once a day in 50 mL of 5% dextrose in water (D/W) over 4 to 6 hours is effective in patients with hypercalcemia due to cancer but is rarely used because other treatments are safer.

Gallium nitrate is also effective in hypercalcemia due to cancer but is used infrequently because of renal toxicity and limited clinical experience.

Severe hypercalcemia

In severe hypercalcemia (serum calcium > 18 mg/dL [> 4.5 mmol/L] or with severe symptoms), hemodialysis with low-calcium dialysate may be needed in addition to other treatments. Although there is no completely satisfactory way to correct severe hypercalcemia in patients with renal failure, hemodialysis Hemodialysis In hemodialysis, a patient’s blood is pumped into a dialyzer containing 2 fluid compartments configured as bundles of hollow fiber capillary tubes or as parallel, sandwiched sheets of semipermeable... read more is probably the safest and most reliable short-term treatment.

IV phosphate (disodium phosphate or monopotassium phosphate) should be used only when hypercalcemia is life threatening and unresponsive to other methods and when short-term hemodialysis is not possible. No more than 1 g should be given IV in 24 hours; usually 1 or 2 doses over 2 days lower serum calcium for 10 to 15 days. Soft-tissue calcification and acute renal failure may result. (NOTE: IV infusion of sodium sulfate is even more hazardous and less effective than phosphate infusion and should not be used.)


Treatment for hyperparathyroidism depends on severity.

Patients with asymptomatic primary hyperparathyroidism with no indications for surgery may be treated conservatively with methods to ensure that serum calcium concentrations remain low. Patients should remain active (ie, avoid immobilization that could exacerbate hypercalcemia), follow a low-calcium diet, drink plenty of fluids to minimize the chance of nephrolithiasis, and avoid drugs that can raise serum calcium, such as thiazide diuretics. Serum calcium and renal function are monitored every 6 months. Bone density is monitored every 12 months. However, subclinical bone disease, hypertension, and longevity are concerns. Osteoporosis is treated with bisphosphonates.

In patients with symptomatic or progressive hyperparathyroidism, surgery is indicated. The indications for surgery in patients with asymptomatic, primary hyperparathyroidism are controversial. Surgical parathyroidectomy increases bone density and may have modest effects on some quality of life symptoms, but most patients do not have progressive deterioration in biochemical abnormalities or bone density. Still, concerns about hypertension and longevity remain. Many experts recommend surgery in the following circumstances:

  • Serum calcium 1 mg/dL (0.25 mmol/L) greater than the upper limits of normal

  • Calciuria > 400 mg/day (> 10 mmol/day)

  • Creatinine clearance < 60 mL/min

  • Peak bone density at the hip, lumbar spine, or radius 2.5 standard deviations below controls (T score =2.5)

  • Age < 50 years

  • The possibility of poor adherence with follow-up

Surgery consists of removal of adenomatous glands. Parathyroid hormone concentration can be measured before and after removal of the presumed abnormal gland using rapid assays. A fall of ≥ 50% 10 minutes after removal of the adenoma indicates successful treatment. In patients with disease of > 1 gland, several glands are removed, and often a small portion of a normal-appearing parathyroid gland is reimplanted in the belly of the sternocleidomastoid muscle or subcutaneously in the forearm to prevent hypoparathyroidism. Parathyroid tissue is also occasionally preserved using cryopreservation to allow for later autologous transplantation in case persistent hypoparathyroidism develops.

When hyperparathyroidism is mild, the serum calcium concentration drops to just below normal within 24 to 48 hours after surgery; serum calcium must be monitored. In patients with severe osteitis fibrosa cystica, prolonged, symptomatic hypocalcemia may occur postoperatively unless 10 to 20 g elemental calcium is given in the days before surgery. Even with preoperative calcium administration, large doses of calcium and vitamin D may be required Treatment Hypocalcemia is a total serum calcium concentration < 8.8 mg/dL (< 2.20 mmol/L) in the presence of normal plasma protein concentrations or a serum ionized calcium concentration < 4... read more ) while bone calcium is repleted.

In patients with severe hypercalcemia with primary hyperparathyroidism who are unable to undergo parathyroidectomy, medical treatment is indicated. Cinacalcet, a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to extracellular calcium, may lower parathyroid hormone and calcium levels.

Hyperparathyroidism in patients with renal failure is usually secondary. Measures used for treatment can also be used for prevention. One aim is to prevent hyperphosphatemia. Treatment combines dietary phosphate restriction and phosphate binding agents, such as calcium carbonate or sevelamer. Despite the use of phosphate binders, dietary restriction of phosphate is needed. Aluminum-containing compounds have been used to limit phosphate concentration, but they should be avoided, especially in patients receiving long-term dialysis, to prevent aluminum accumulation in bone resulting in severe osteomalacia. Vitamin D administration is potentially hazardous in renal failure because it can increase phosphate absorption and contribute to hypercalcemia; administration requires frequent monitoring of calcium and phosphate levels. Treatment should be limited to patients with any of the following:

  • Symptomatic osteomalacia (unrelated to aluminum)

  • Secondary hyperparathyroidism

  • Postparathyroidectomy hypocalcemia

Although oral calcitriol is often given along with oral calcium to suppress secondary hyperparathyroidism, the results are variable in patients with end-stage renal disease. The parenteral form of calcitriol, or vitamin D analogs such as paricalcitol, may better prevent secondary hyperparathyroidism in such patients, because the higher attained serum concentration of 1,25(OH)2D directly suppresses PTH release. Simple osteomalacia may respond to calcitriol 0.25 to 0.5 mcg orally once a day, whereas correction of postparathyroidectomy hypocalcemia may require prolonged administration of as much as 2 mcg of calcitriol po once/day and 2 g of elemental calcium/day.

The calcimimetic, cinacalcet, modulates the set point of the calcium-sensing receptor on parathyroid cells and decreases PTH concentration in dialysis patients without increasing serum calcium. In patients with osteomalacia caused by having taken large amounts of aluminum-containing phosphate binders, removal of aluminum with deferoxamine is necessary before calcitriol administration reduces bone lesions.

Familial hypocalciuric hypercalcemia

Although FHH results from histologically abnormal parathyroid tissue, the response to subtotal parathyroidectomy is unsatisfactory. Because overt clinical manifestations are rare, drug therapy is not routinely indicated.

Key Points

  • The most common causes of hypercalcemia are hyperparathyroidism and cancer.

  • Clinical features include polyuria, constipation, anorexia, and hypercalciuria with renal stones; patients with high calcium concentrations may have muscle weakness, confusion, and coma.

  • Do chest x-ray; measure electrolytes, blood urea nitrogen, creatinine, ionized calcium, phosphate, parathyroid hormone, and alkaline phosphatase, and do serum protein immunoelectrophoresis.

  • In addition to treating the cause, treat mild hypercalcemia (serum calcium < 11.5 mg/dL [< 2.9 mmol/L]) with oral phosphate or isotonic saline plus a loop diuretic.

  • For moderate hypercalcemia (serum calcium > 11.5 mg/dL [< 2.9 mmol/L] and < 18 mg/dL [< 4.5 mmol/L]), add a bisphosphonate, corticosteroids, and sometimes calcitonin.

  • For severe hypercalcemia, hemodialysis may be needed.

Drugs Mentioned In This Article

Drug Name Select Trade
Calcidol, Calciferol, D3 Vitamin, DECARA, Deltalin, Dialyvite Vitamin D, Dialyvite Vitamin D3, Drisdol, D-Vita, Enfamil D-Vi-Sol, Ergo D, Fiber with Vitamin D3 Gummies Gluten-Free, Happy Sunshine Vitamin D3, MAXIMUM D3, PureMark Naturals Vitamin D, Replesta, Replesta Children's, Super Happy SUNSHINE Vitamin D3, Thera-D 2000, Thera-D 4000, Thera-D Rapid Repletion, THERA-D SPORT, UpSpring Baby Vitamin D, UpSpring Baby Vitamin D3, YumVs, YumVs Kids ZERO, YumVs ZERO
AcidFree, Alka-Mints, Alka-Seltzer, Alka-Seltzer Heartburn Relief, Alkets , Antacid Fast Dissolve, Calcarb 600, Calci-Chew , Calci-Mix , Calcium Antacid, Cal-Gest , Caltrate, Maalox, Maalox Antacid Barrier, Maalox Quick Dissolve, Mylanta Children's, Nephro-Calci , Pepto-Bismol Children's, Rolaids Extra Strength, Titralac, Titralac Extra Strength, Tums, Tums Chewy Bites , Tums Cool Relief, Tums E-X, Tums Freshers, Tums Kids, Tums Lasting Effects, Tums Smooth Dissolve, Tums Smoothies, Tums Ultra
Digitek , Lanoxicaps, Lanoxin, Lanoxin Pediatric
Aluvea , BP-50% Urea , BP-K50, Carmol, CEM-Urea, Cerovel, DermacinRx Urea, Epimide-50, Gord Urea, Gordons Urea, Hydro 35 , Hydro 40, Kerafoam, Kerafoam 42, Keralac, Keralac Nailstik, Keratol, Keratol Plus, Kerol, Kerol AD, Kerol ZX, Latrix, Mectalyte, Nutraplus, RE Urea 40, RE Urea 50 , Rea Lo, Remeven, RE-U40, RYNODERM , U40, U-Kera, Ultra Mide 25, Ultralytic-2, Umecta, Umecta Nail Film, URALISS, Uramaxin , Uramaxin GT, Urea, Ureacin-10, Ureacin-20, Urealac , Ureaphil, Uredeb, URE-K , Uremez-40, Ure-Na, Uresol, Utopic, Vanamide, Xurea, X-VIATE
Albuked , Albumarc, Albuminar, Albuminex, AlbuRx , Albutein, Buminate, Flexbumin, Kedbumin, Macrotec, Plasbumin, Plasbumin-20
Delone , FUROSCIX, Lasix
Calcijex, Rocaltrol, Vectical
Fortical , Miacalcin
Binosto, Fosamax
Actonel, Atelvia
Prolia, XGEVA
Deltasone, Predone, RAYOS, Sterapred, Sterapred DS
Advocate Glucose SOS, BD Glucose, Dex4 Glucose, Glutol , Glutose 15 , Glutose 45 , Glutose 5
RenaGel, Renvela
Zemplar, Zemplar Multi-Dose Vial Solution, Zemplar Solution
View Patient Education
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz!